Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell Activation
While liquiritigenin, isolated from <i>Spatholobus suberectus Dunn</i>, is known to possess anti-inflammatory activities, it still remains to be known whether liquiritigenin has a suppressive effect on T cell activation and T cell-mediated disease. Here, we used Jurkat T cells to explore...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/10/5/786 |
| _version_ | 1797567590390824960 |
|---|---|
| author | Hyun-Su Lee Eun-Nam Kim Gil-Saeng Jeong |
| author_facet | Hyun-Su Lee Eun-Nam Kim Gil-Saeng Jeong |
| author_sort | Hyun-Su Lee |
| collection | DOAJ |
| description | While liquiritigenin, isolated from <i>Spatholobus suberectus Dunn</i>, is known to possess anti-inflammatory activities, it still remains to be known whether liquiritigenin has a suppressive effect on T cell activation and T cell-mediated disease. Here, we used Jurkat T cells to explore an underlying mechanism of pre-treatment with liquiritigenin in activated T cell in vitro and used atopic dermatitis (AD) in vivo to confirm it. We found liquiritigenin blocks IL-2 and CD69 expression from activated T cells by PMA/A23187 or anti-CD3/CD28 antibodies. The expressions of surface molecules, including CD40L and CD25, were also reduced in activated T cells pre-treated with liquiritigenin. Western blot analysis indicated repressive effects by liquiritigenin are involved in NFκB and MAPK pathways. To assess the effects of liquiritigenin in vivo, an AD model was applied as T cell-mediated disease. Oral administration of liquiritigenin attenuates AD manifestations, including ear thickness, IgE level, and thicknesses of dermis and epidermis. Systemic protections by liquiritigenin were observed to be declined in size and weight of draining lymph nodes (dLNs) and expressions of effector cytokines from CD4<sup>+</sup> T cells in dLNs. These results suggest liquiritigenin has an anti-atopic effect via control of T cell activation and exhibits therapeutic potential for T cell-mediated disorders. |
| first_indexed | 2024-03-10T19:44:07Z |
| format | Article |
| id | doaj.art-bad27e440b6b48c093e8313577d4fbdc |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T19:44:07Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-bad27e440b6b48c093e8313577d4fbdc2023-11-20T00:59:01ZengMDPI AGBiomolecules2218-273X2020-05-0110578610.3390/biom10050786Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell ActivationHyun-Su Lee0Eun-Nam Kim1Gil-Saeng Jeong2College of Pharmacy, Keimyung University, Daegu 42601, KoreaCollege of Pharmacy, Keimyung University, Daegu 42601, KoreaCollege of Pharmacy, Keimyung University, Daegu 42601, KoreaWhile liquiritigenin, isolated from <i>Spatholobus suberectus Dunn</i>, is known to possess anti-inflammatory activities, it still remains to be known whether liquiritigenin has a suppressive effect on T cell activation and T cell-mediated disease. Here, we used Jurkat T cells to explore an underlying mechanism of pre-treatment with liquiritigenin in activated T cell in vitro and used atopic dermatitis (AD) in vivo to confirm it. We found liquiritigenin blocks IL-2 and CD69 expression from activated T cells by PMA/A23187 or anti-CD3/CD28 antibodies. The expressions of surface molecules, including CD40L and CD25, were also reduced in activated T cells pre-treated with liquiritigenin. Western blot analysis indicated repressive effects by liquiritigenin are involved in NFκB and MAPK pathways. To assess the effects of liquiritigenin in vivo, an AD model was applied as T cell-mediated disease. Oral administration of liquiritigenin attenuates AD manifestations, including ear thickness, IgE level, and thicknesses of dermis and epidermis. Systemic protections by liquiritigenin were observed to be declined in size and weight of draining lymph nodes (dLNs) and expressions of effector cytokines from CD4<sup>+</sup> T cells in dLNs. These results suggest liquiritigenin has an anti-atopic effect via control of T cell activation and exhibits therapeutic potential for T cell-mediated disorders.https://www.mdpi.com/2218-273X/10/5/786liquiritigeninT cell activationCD69MAPKatopic dermatitislymph nodes |
| spellingShingle | Hyun-Su Lee Eun-Nam Kim Gil-Saeng Jeong Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell Activation Biomolecules liquiritigenin T cell activation CD69 MAPK atopic dermatitis lymph nodes |
| title | Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell Activation |
| title_full | Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell Activation |
| title_fullStr | Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell Activation |
| title_full_unstemmed | Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell Activation |
| title_short | Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell Activation |
| title_sort | oral administration of liquiritigenin confers protection from atopic dermatitis through the inhibition of t cell activation |
| topic | liquiritigenin T cell activation CD69 MAPK atopic dermatitis lymph nodes |
| url | https://www.mdpi.com/2218-273X/10/5/786 |
| work_keys_str_mv | AT hyunsulee oraladministrationofliquiritigeninconfersprotectionfromatopicdermatitisthroughtheinhibitionoftcellactivation AT eunnamkim oraladministrationofliquiritigeninconfersprotectionfromatopicdermatitisthroughtheinhibitionoftcellactivation AT gilsaengjeong oraladministrationofliquiritigeninconfersprotectionfromatopicdermatitisthroughtheinhibitionoftcellactivation |